Hindustan Laboratories IPO Details
MAINBOARD
Hindustan Laboratories IPO DRHP (Draft Red Herring Prospectus) has been Filed With SEBI.
Hindustan Laboratories IPO total issue size comprises 1,41,00,000 shares (aggregating up to ₹0.00 Cr.). This includes a fresh issue of 50,00,000 shares (aggregating up to ₹0.00 Cr.). Offer for Sale consists of 91,00,000 shares (aggregating up to ₹0.00 Cr.).
The Lead Managers for Hindustan Laboratories IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Choice Capital Advisors Pvt.Ltd.. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Hindustan Laboratories Limited DRHP.
Hindustan Laboratories IPO Details
Hindustan Laboratories IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Hindustan Laboratories IPO Reservation
Promoter Holding
Documents
Hindustan Laboratories IPO Valuations
Hindustan Laboratories Financial Information
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 242.95 | 225.49 | 176.35 | 145.40 |
| Total Income | 115.78 | 227.37 | 194.33 | 179.48 |
| Profit After Tax | 18.24 | 41.27 | 34.14 | 22.25 |
| EBITDA | 25.46 | 53.88 | 44.09 | 30.69 |
| NET Worth | 197.01 | 178.74 | 137.34 | 103.15 |
| Total Borrowing | 3.85 | 6.79 | 5.11 | 1.50 |
| Amount in ₹ Crore | ||||
About Hindustan Laboratories IPO
Hindustan Laboratories Limited was incorporated in 2017 and is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines under a business-to-government (B2G) model. The Company focuses on supplying affordable and essential medicines to public healthcare systems across India.
The Company supplies pharmaceutical products mainly through procurement contracts for central government healthcare programmes under the Ministry of Health and Family Welfare, executed via Government of India agencies, as well as through state government agencies and public bodies. This B2G-focused operating model enables Hindustan Laboratories Limited to participate in large-volume, long-term public health initiatives.
Geographic Reach and Customer Base
During the six months ended September 30, 2025, the Company supplied products across 27 states and Union Territories, a coverage level also achieved during Fiscal 2025. The Company served 343 customers during the six months ended September 30, 2025, and 445, 474, and 439 customers in Fiscal 2025, Fiscal 2024, and Fiscal 2023, respectively, reflecting a broad and recurring government customer base.
Product Portfolio
The Company’s portfolio spans a wide range of acute and chronic therapeutic segments, including:
- Anti-allergic
- Anti-diabetic
- Anti-infective
- Anti-malarial and antiparasitic
- Blood-related therapies
- Cardiac and gastrointestinal therapies
- Keratolytic, pain management and analgesics
- Respiratory therapies
- Nutritional, mineral, and vitamin supplements
Hindustan Laboratories Limited has formulation capabilities across multiple dosage forms, including tablets, capsules, powders, oral liquids, topical solutions, creams, ointments, combination blister packs, and topical powders. Its product portfolio has expanded from 661 products as of March 31, 2023, to 871 products as of March 31, 2025, and further to 948 products as of September 30, 2025, demonstrating consistent portfolio growth.
Manufacturing Infrastructure
The Company operates its primary manufacturing facility (Unit 1) at Palghar, Maharashtra, approximately 100 km from Mumbai, with connectivity via road, rail, and air along National Highway 8. The facility is ISO 9001:2015 certified for quality management systems.
An additional manufacturing unit (Unit 2) is located at the same Palghar site and has been developed to support future capacity expansion. Unit 2 is currently under commissioning, and commercial production has not yet commenced.
Human Resources
As of September 30, 2025, the Company’s workforce comprised 284 employees and 332 contract labourers, supporting manufacturing, quality assurance, logistics, and administrative functions.
With its B2G-focused business model, diversified therapeutic portfolio, expanding manufacturing capacity, and pan-India reach, Hindustan Laboratories Limited plays a significant role in supporting India’s public healthcare supply chain.
Strength Of Hindustan Laboratories IPO
Risk Of Hindustan Laboratories IPO
Objectives Hindustan Laboratories IPO
To be announced
Company Contact Details
Hindustan Laboratories Ltd. Address
302, A Wing, Victory Park, Chandavarkar Road,
Borivali West, Mumbai, Maharashtra, 400092
Phone: 022-42460500
Email: compliance@hindlab.com
Website: https://hindustanlaboratories.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Hindustan Laboratories IPO - FAQs
The Hindustan Laboratories IPO is a MAINBOARD public issue comprising 14100000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹0.00 Cr.. The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.